OneOncology, the national partnership of independent oncology practices, today appointed John Fox, MD as Medical Director, Managed Care.
Nashville, TN, July 20, 2020 — OneOncology, the national partnership of independent oncology practices, today appointed John Fox, MD as Medical Director, Managed Care. In his role, Fox will work with OneOncology partner practices to develop, evolve and maintain value-based contracts with commercial and public payers.
“As the transition from fee-for-service to value-based contacts continues, Dr. Fox will play an integral role supporting partner practices to develop and optimize value-based care to achieve Quadruple AIM goals,” said Jeff Patton, MD, CEO, OneOncology.
A recognized leader in practice transformation, OneOncology bolsters partner practices’ capacity for value-base care delivery through alternative payment model design and implementation, public policy advocacy and thought leadership, commercial health plan contract negotiation, and physician engagement and education initiatives.
OneOncology partner practices have collectively managed 4,500 episodes of care in each performance period of the Center for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM). OneOncology partner practices also participate in several commercial health plan value-based payment arrangements. OneOncology provides a scalable platform for generating insights, sharing best practices, and benchmarking key performance metrics among several of the most progressive practices in value-based care.
Read the full press release here.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More